Marcus Schmitt-Egenolf

Professor/chief physician at Department of Public Health and Clinical Medicine Units: Medicine, Dermatology and Venereology

marcus.schmitt-egenolf@umu.se

+46 90 786 54 72

1A, målpunkt B41, enheten för medicin, Norrlands Universitetssjukhus Umeå universitet, 901 87 Umeå

Latest publications

2018

Sustained Psoriasis Area and Severity Index, DermatologyLife Quality Index and EuroQol-5D response of biologicaltreatment in psoriasis: 10 years of real-world data in theSwedish National Psoriasis Register

British Journal of Dermatology, Hoboken: John Wiley & Sons 2018, Vol. 178, (1) : 245-252

Hjalte, F.; Steen Carlsson, K.; Schmitt-Egenolf, Marcus

2018

What can we learn from 'dropouts' in clinical trials?

British Journal of Dermatology, John Wiley & Sons 2018, Vol. 178, (2) : 318-319

Schmitt-Egenolf, Marcus

2017

How is disease severity associated with quality of life in psoriasis patients?: Evidence from a longitudinal population-based study in Sweden

Health and Quality of Life Outcomes, Vol. 15, (1)

Geale, Kirk; Henriksson, Martin; Schmitt-Egenolf, Marcus

2017

Real-world outcomes in 2,646 psoriasis patients: one in five has PASI ≥ 10 and/or DLQI ≥ 10 under ongoing systemic therapy

Journal of dermatological treatment (Print), Vol. 28, (6) : 500-504

Norlin, J. M.; Calara, P. S.; Persson, U.; et al.

2017

Regional Differences in the Prescription of Biologics for Psoriasis in Sweden: a Register-Based Study of 4168 Patients

BioDrugs, Vol. 31, (1) : 75-82

Calara, Paul S; Althin, Rikard; Carlsson, Katarina Steen; et al.

2017

Severity of psoriasis differs between men and women: a registry based study of the clinical outcome measure Psoriasis Area and Severity Index (PASI) in 5438 patients

American Journal of Clinical Dermatology, Vol. 18 : 583-590

Hägg, David; Sundström, Anders; Eriksson, Marie; et al.

2016

Evaluating equality in psoriasis healthcare: a cohort study of the impact of age on prescription biologics

British Journal of Dermatology, Vol. 174, (3) : 579-587

Gaele, Kirk; Henriksson, Martin; Schmitt-Egenolf, Marcus

2016

Healthcare Provider Type and Switch to Biologics in Psoriasis: Evidence from Real-World Practice

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, Vol. 30, (2) : 145-151

Calara, Paul S.; Norlin, Jenny M.; Althin, Rikard; et al.

2016

Periodontal Ehlers-Danlos Syndrome Is Caused by Mutations in C1R and C1S, which Encode Subcomponents C1r and C1s of Complement

American Journal of Human Genetics, Cell Press 2016, Vol. 99, (5) : 1005-1014

Kapferer-Seebacher, Ines; Pepin, Melanie; Werner, Roland; et al.

2016

Physical activity and lifestyle improvement in the management of psoriasis

British Journal of Dermatology, Vol. 175, (3) : 452-453

Schmitt-Egenolf, Marcus

2016

Psoriasis Patients New to Specialist Care in Sweden 2007-2009: A Two-Year Follow-Up of Treatment Allocation

Pharmacoepidemiology and Drug Safety, Wiley-Blackwell 2016, Vol. 25 : 4-5

Hägg, David; Eriksson, Marie; Schmitt-Egenolf, Marcus; et al.

2015

Decision for biological treatment in real life is more strongly associated with the Psoriasis Area and Severity Index (PASI) than with the Dermatology Life Quality Index (DLQI)

Journal of the European Academy of Dermatology and Venereology, John Wiley & Sons 2015, Vol. 29, (3) : 452-456

Hägg, David; Sundström, A; Eriksson, Marie; et al.

2015

Hair shaft structures in EDAR induced ectodermal dysplasia

BMC Medical Genetics, BioMed Central 2015, Vol. 16

Stecksén-Blicks, Christina; Falk Kieri, Catharina; Schmitt-Egenolf, Marcus; et al.

2015

Real-world outcome analysis of continuously and intermittently treated patients with moderate to severe psoriasis after switching to a biologic agent

Dermatology, S. Karger 2015, Vol. 230, (4) : 347-353

Hjalte, Frida; Steen Carlsson, Katarina; Schmitt-Egenolf, Marcus

2015

Register-Based Evaluation of Relative Effectiveness of New Therapies: Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden

BioDrugs, Vol. 29, (6) : 389-398

Norlin, Jenny M.; Steen Carlsson, Katarina; Persson, Ulf; et al.

2015

Resource use in patients with psoriasis after the introduction of biologics in Sweden

Acta Dermato-Venereologica, Vol. 95, (2) : 156-161

Norlin, Jenny M.; Steen Carlsson, Katarina; Persson, Ulf; et al.

2015

The Relationship Between Disease Severity and Quality of Life In Patients With Moderate to Severe Psoriasis

Value in Health, Vol. 18, (7) : A675-A675

Geale, Kirk; Henriksson, M.; Schmitt-Egenolf, Marcus

2014

EDAR-induced hypohidrotic ectodermal dysplasia: a clinical study on signs and symptoms in individuals with a heterozygous c.1072C > T mutation

BMC Medical Genetics, BioMed Central 2014, Vol. 15 : 57-

Falk Kieri, Catarina; Bergendal, Birgitta; Lind, Lisbet K; et al.

2014

Health care delay in malignant melanoma: various pathways to diagnosis and treatment

Dermatology Research and Practice, Hindawi Publishing Corporation 2014 : 294287-

Hajdarevic, Senada; Hörnsten, Åsa; Sundbom, Elisabet; et al.

2014

Registerstudier mäter effektivitet av läkemedel i klinisk praxis: Exemplet PsoReg – omfördelning av systemisk terapi kan ge ökad effektivitet

Läkartidningen, Vol. 111, (24) : 1061-3

Norlin, Jenny; Schmitt-Egenolf, Marcus; Steen Carlsson, Katarina; et al.

2013

Coping styles in decision making among men and women diagnosed with malignant melanoma

Journal of Health Psychology, Sage Publications 2013, Vol. 18, (11) : 1445-1455

Hajdarevic, Senada; Schmitt-Egenolf, Marcus; Sundbom, Elisabet; et al.

2013

The higher proportion of men with psoriasis treated with biologics may be explained by more severe disease in men

PLoS ONE, Public library of science 2013, Vol. 8, (5) : e63619-

Hägg, David; Eriksson, Marie; Sundström, Anders; et al.

2012

Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients

British Journal of Dermatology, Wiley-Blackwell 2012, Vol. 166, (4) : 797-802

Norlin, Jenny M; Steen Carlsson, K; Persson, U; et al.

2012

Challenges for synthesising data in a network of registries for systemic Psoriasis therapies

Dermatology, S. Karger 2012, Vol. 224, (3) : 236-243

Ormerod, AD; Augustin, M; Baker, C; et al.

2012

Switch to biological agent in psoriasis significantly improved clinical and patient-reported outcomes in real-world practice

Dermatology, S. Karger 2012, Vol. 225, (4) : 326-332

Norlin, Jenny M; Steen Carlsson, Katarina; Persson, Ulf; et al.

2011

Malignant melanoma: gender patterns in care seeking for suspect marks

Journal of Clinical Nursing, Wiley-Blackwell 2011, Vol. 20, (17-18) : 2676-2684

Hajdarevic, Senada; Schmitt-Egenolf, Marcus; Brulin, Christine; et al.

2010

Patients' decision making in seeking care for suspected malignant melanoma

Journal of Nursing and Healthcare of Chronic Illness, Wiley-Blackwell 2010, Vol. 2, (2) : 164-173

Hajdarevic, Senada; Hörnsten, Åsa; Sundbom, Elisabet; et al.

2009

How dermatologists can evaluate systemic psoriasis treatments

Forum for nordic dermato-venereology, Vol. 14, (2) : 38-40

Schmitt-Egenolf, Marcus

2008

Switching biologicals: switching TNFalpha antagonists in psoriasis treatment

Dermatology, S. Karger 2008, Vol. 216, (4) : 281-282

Schmitt-Egenolf, Marcus

2007

PsoReg: the Swedish registry for systemic psoriasis treatment. The registry's design and objectives.

Dermatology, S. Karger 2007, Vol. 214, (2) : 112-117

Schmitt-Egenolf, Marcus

2006

EDAR mutation in autosomal dominant hypohidrotic ectodermal dysplasia in two Swedish families

BMC Medical Genetics, BioMed Central 2006, Vol. 7 : 80-

Lind, Lisbet K; Stecksén-Blicks, Christina; Lejon, Kristina; et al.

2006

Psoriasis therapy in real life: the need for registries

Dermatology, S. Karger 2006, Vol. 213, (4) : 327-330

Schmitt-Egenolf, Marcus

2004

Pso-Reg: the quality register for systemic psoriasis treatment

Forum for Nordic dermato-venereology, Nordic dermatological association 2004, Vol. 9, (4) : 94-97

Schmitt-Egenolf, Marcus

2003

Association scan of the novel psoriasis susceptibility region on chromosome 19: evidence for both susceptible and protective loci

Experimental dermatology, John Wiley & Sons 2003, Vol. 12, (4) : 490-496

Hensen, P; Windemuth, C; Hüffmeier, U; et al.

2003

Interleukin-10 promoter polymorphism IL10.G and familial early onset psoriasis

British Journal of Dermatology, John Wiley & Sons 2003, Vol. 149, (2) : 381-385

Hensen, P; Asadullah, K; Windemuth, C; et al.

2001

Comparative association analysis reveals that corneodesmosin is more closely associated with psoriasis than HLA-Cw*0602-B*5701 in German families

Tissue Antigens, John Wiley & Sons 2001, Vol. 57, (5) : 440-446

Schmitt-Egenolf, Marcus; Windemuth, C; Hennies, HC; et al.

2000

Genomewide scan in german families reveals evidence for a novel psoriasis-susceptibility locus on chromosome 19p13

American Journal of Human Genetics, Elsevier 2000, Vol. 67, (4) : 1020-1024

Lee, YA; Rüschendorf, F; Windemuth, C; et al.

2000

PERB11 (MIC): a polymorphic MHC gene is expressed in skin and single nucleotide polymorphisms are associated with psoriasis.

Clinical and Experimental Immunology, John Wiley & Sons 2000, Vol. 119, (3) : 553-558

Tay, GK; Hui, J; Gaudieri, S; et al.

1999

Promoter polymorphism at -238 of the tumor necrosis factor alpha gene is not associated with early onset psoriasis when tested by the transmission disequilibrium test

Journal of Investigative Dermatology, Nature Publishing Group 1999, Vol. 112, (4) : 513-514

Jacob, N; Rüschendorf, F; Schmitt-Egenolf, Marcus; et al.

1999

Survival, maturation, and function of CD11c- and CD11c+ peripheral blood dendritic cells are differentially regulated by cytokines

Journal of Immunology, American association of immunologists 1999, Vol. 163, (6) : 3250-3259

Kohrgruber, N; Halanek, N; Gröger, M; et al.

1997

Association between interleukin-1 receptor antagonist (IL-1ra) gene polymorphism and early and late-onset psoriasis

British Journal of Dermatology, John Wiley & Sons 1997, Vol. 136, (1) : 147-148

Tarlow, JK; Cork, MJ; Clay, FE; et al.

1996

Familial juvenile onset psoriasis is associated with the human leukocyte antigen (HLA) class I side of the extended haplotype Cw6-B57-DRB1*0701-DQA1*0201-DQB1*0303: a population- and family-based study

Journal of Investigative Dermatology, Nature Publishing Group 1996, Vol. 106, (4) : 711-714

Schmitt-Egenolf, Marcus; Eiermann, TH; Boehncke, WH; et al.

1996

Peripheral blood dendritic cells express Fc epsilon RI as a complex composed of Fc epsilon RI alpha- and Fc epsilon RI gamma-chains and can use this receptor for IgE-mediated allergen presentation

Journal of Immunology, American association of immunologists 1996, Vol. 157, (2) : 607-616

Maurer, D; Fiebiger, S; Ebner, C; et al.

1994

Analysis of TAP2 and HLA-DP gene polymorphism in psoriasis

Human Immunology, Vol. 40, (4) : 299-302

Fakler, JW; Schmitt-Egenolf, Marcus; Vejbaesya, S; et al.

1994

Polymorphism in an HLA linked proteasome gene influences phenotypic expression of disease in HLA-B27 positive individuals

Journal of Rheumatology, Vol. 21, (4) : 665-669

Maksymowych, WP; Wessler, A; Schmitt-Egenolf, Marcus; et al.

1993

Oligonucleotide typing reveals association of type I psoriasis with the HLA-DRB1*0701/2, -DQA1*0201, -DQB1*0303 extended haplotype

Journal of Investigative Dermatology, Nature Publishing Group 1993, Vol. 100, (6) : 749-752

Schmitt-Egenolf, Marcus; Boehncke, WH; Ständer, M; et al.

1991

Type I and type II psoriasis show a similar usage of T-cell receptor variable regions

Journal of Investigative Dermatology, Nature Publishing Group 1991, Vol. 97, (6) : 1053-1056

Schmitt-Egenolf, Marcus; Boehncke, WH; Christophers, E; et al.

View publications in DiVA Close
Research projects

2010-10-06

Melanoma, a new approach to decrease delay of diagnosis and treatment

Schmitt-Egenolf, Marcus

Close

Marcus Schmitt-Egenolf

Latest publications

Research projects